Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650011 | 0.91 | AGER (0.79) | AGERSLC6A4 | |
| SCHEMBL1283731 | 0.91 | AGER (0.68) | AGER | |
| SCHEMBL18649947 | 0.89 | AGER (0.62) | AGER | |
| SCHEMBL23631278 | 0.87 | AGER (1.00) | AGERSLC6A4 | |
| SCHEMBL3508025 | 0.87 | AGER (0.86) | AGER | |
| SCHEMBL18650027 | 0.87 | AGER (0.86) | AGER | |
| SCHEMBL23631271 | 0.86 | AGER (1.00) | AGER | |
| SCHEMBL1283514 | 0.85 | AGER (1.00) | AGER | |
| Azeliragon SCHEMBL1142599 | 0.85 | AGER (1.00) | AGER | |
| SCHEMBL1577173 | 0.85 | AGER (0.69) | AGERSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-11524942-B2 | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine | VTV THERAPEUTICS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210214314-A1 | METABOLITES OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2021-07-15 | — | — | US | disclosed |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | VTV THERAPEUTICS LLC | 2017-06-08 | — | — | US | disclosed |
| US-9598375-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2324830-A1 | Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage | TransTech Pharma Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP11B2, CYP2C19, SLC10A2 | AGER 1632/4885SLC6A4 310/4885 |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP3A7, CYP3A5, CYP3A43 | AGER 3594/4885SLC6A4 273/4885 |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | CYP3A7, CYP3A5, CYP3A43 | AGER 3594/4885SLC6A4 273/4885 |
| US-11524942-B2 | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine | AGER, GPR174, P2RY4 | AGER 1/4885SLC6A4 397/4885 |
| US-20210214314-A1 | METABOLITES OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | AGER, GPR174, P2RY4 | AGER 1/4885SLC6A4 397/4885 |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | AGER, GPR174, P2RY4 | AGER 1/4885SLC6A4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.